164 related articles for article (PubMed ID: 7865902)
1. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Cheng MF; Chatterjee S; Berger NA
Oncol Res; 1994; 6(6):269-79. PubMed ID: 7865902
[TBL] [Abstract][Full Text] [Related]
2. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
Holm C; Covey JM; Kerrigan D; Pommier Y
Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity to DNA cross-linking agents associated with up-regulation of glucose-regulated stress protein GRP78.
Chatterjee S; Hirota H; Belfi CA; Berger SJ; Berger NA
Cancer Res; 1997 Nov; 57(22):5112-6. PubMed ID: 9371511
[TBL] [Abstract][Full Text] [Related]
4. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
Friedman HS; Dolan ME; Kaufmann SH; Colvin OM; Griffith OW; Moschel RC; Schold SC; Bigner DD; Ali-Osman F
Cancer Res; 1994 Jul; 54(13):3487-93. PubMed ID: 8012971
[TBL] [Abstract][Full Text] [Related]
5. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
6. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
Whitacre CM; Zborowska E; Gordon NH; Mackay W; Berger NA
Cancer Res; 1997 Apr; 57(8):1425-8. PubMed ID: 9108439
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
8. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Bible KC; Kaufmann SH
Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999
[TBL] [Abstract][Full Text] [Related]
10. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
11. Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line.
Pu QQ; Bezwoda WR
Anticancer Res; 2000; 20(4):2569-78. PubMed ID: 10953328
[TBL] [Abstract][Full Text] [Related]
12. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864).
Mattern MR; Hofmann GA; McCabe FL; Johnson RK
Cancer Res; 1991 Nov; 51(21):5813-6. PubMed ID: 1657371
[TBL] [Abstract][Full Text] [Related]
13. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells.
Hennequin C; Giocanti N; Balosso J; Favaudon V
Cancer Res; 1994 Apr; 54(7):1720-8. PubMed ID: 8137287
[TBL] [Abstract][Full Text] [Related]
14. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
15. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
Traganos F; Kapuscinski J; Gong J; Ardelt B; Darzynkiewicz RJ; Darzynkiewicz Z
Cancer Res; 1993 Oct; 53(19):4613-8. PubMed ID: 8402636
[TBL] [Abstract][Full Text] [Related]
16. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
Danks MK; Pawlik CA; Whipple DO; Wolverton JS
Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
[TBL] [Abstract][Full Text] [Related]
17. DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide.
Giocanti N; Hennequin C; Balosso J; Mahler M; Favaudon V
Cancer Res; 1993 May; 53(9):2105-11. PubMed ID: 8386982
[TBL] [Abstract][Full Text] [Related]
18. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
20. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors.
Kuo CC; Liu JF; Chang JY
J Pharmacol Exp Ther; 2006 Feb; 316(2):946-54. PubMed ID: 16258022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
